{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:52:29Z","timestamp":1776779549779,"version":"3.51.2"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"crossref","award":["PG13-026"],"award-info":[{"award-number":["PG13-026"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Accurate whole-body staging following biochemical relapse in prostate cancer is vital in determining the optimum disease management. Current imaging guidelines recommend various imaging platforms such as computed tomography (CT), Technetium 99\u2009m (<jats:sup>99m<\/jats:sup>Tc) bone scan and <jats:sup>18<\/jats:sup>F-choline and recently <jats:sup>68<\/jats:sup>Ga-PSMA positron emission tomography (PET) for the evaluation of the extent of disease. Such approach requires multiple hospital attendances and can be time and resource intensive. Recently, whole-body magnetic resonance imaging (WB-MRI) has been used in a single visit scanning session for several malignancies, including prostate cancer, with promising results, providing similar accuracy compared to the combined conventional imaging techniques. The LOCATE trial aims to investigate the application of WB-MRI for re-staging of patients with biochemical relapse (BCR) following external beam radiotherapy and brachytherapy in patients with prostate cancer.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods\/design<\/jats:title>\n<jats:p>The LOCATE trial is a prospective cohort, multi-centre, non-randomised, diagnostic accuracy study comparing WB-MRI and conventional imaging. Eligible patients will undergo WB-MRI in addition to conventional imaging investigations at the time of BCR and will be asked to attend a second WB-MRI exam, 12-months following the initial scan. WB-MRI results will be compared to an enhanced reference standard comprising all the initial, follow-up imaging and non-imaging investigations. The diagnostic performance (sensitivity and specificity analysis) of WB-MRI for re-staging of BCR will be investigated against the enhanced reference standard on a per-patient basis. An economic analysis of WB-MRI compared to conventional imaging pathways will be performed to inform the cost-effectiveness of the WB-MRI imaging pathway. Additionally, an exploratory sub-study will be performed on blood samples and exosome-derived human epidermal growth factor receptor (HER) dimer measurements will be taken to investigate its significance in this cohort.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>The LOCATE trial will compare WB-MRI versus the conventional imaging pathway including its cost-effectiveness, therefore informing the most accurate and efficient imaging pathway.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>LOCATE trial was registered on ClinicalTrial.gov on 18th of October 2016 with registration reference number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrial.gov\/\">NCT02935816<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12880-019-0380-y","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T16:02:32Z","timestamp":1573833752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole\u2013body magnetic resonance imaging in radio-recurrent prostate cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Sola","family":"Adeleke","sequence":"first","affiliation":[]},{"given":"Arash","family":"Latifoltojar","sequence":"additional","affiliation":[]},{"given":"Harbir","family":"Sidhu","sequence":"additional","affiliation":[]},{"given":"Myria","family":"Galazi","sequence":"additional","affiliation":[]},{"given":"Taimur T.","family":"Shah","sequence":"additional","affiliation":[]},{"given":"Joey","family":"Clemente","sequence":"additional","affiliation":[]},{"given":"Reena","family":"Davda","sequence":"additional","affiliation":[]},{"given":"Heather Ann","family":"Payne","sequence":"additional","affiliation":[]},{"given":"Manil D.","family":"Chouhan","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Lioumi","sequence":"additional","affiliation":[]},{"given":"Sue","family":"Chua","sequence":"additional","affiliation":[]},{"given":"Alex","family":"Freeman","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Rodriguez-Justo","sequence":"additional","affiliation":[]},{"given":"Anthony","family":"Coolen","sequence":"additional","affiliation":[]},{"given":"Sachin","family":"Vadgama","sequence":"additional","affiliation":[]},{"given":"Steve","family":"Morris","sequence":"additional","affiliation":[]},{"given":"Gary J.","family":"Cook","sequence":"additional","affiliation":[]},{"given":"Jamshed","family":"Bomanji","sequence":"additional","affiliation":[]},{"given":"Manit","family":"Arya","sequence":"additional","affiliation":[]},{"given":"Simon","family":"Chowdhury","sequence":"additional","affiliation":[]},{"given":"Simon","family":"Wan","sequence":"additional","affiliation":[]},{"given":"Athar","family":"Haroon","sequence":"additional","affiliation":[]},{"given":"Tony","family":"Ng","sequence":"additional","affiliation":[]},{"given":"Hashim Uddin","family":"Ahmed","sequence":"additional","affiliation":[]},{"given":"Shonit","family":"Punwani","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"380_CR1","unstructured":"http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer#heading-Zero- Accessed 18th of June 2019."},{"issue":"2","key":"380_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13566-015-0191-x","volume":"4","author":"M Naik","year":"2015","unstructured":"Naik M, Marta GN, Abdel-Wahab M. Reirradiation of locally recurrent prostate cancer after primary radiotherapy. J Radiat Oncol. 2015;4(2):149\u201356.","journal-title":"J Radiat Oncol"},{"issue":"4","key":"380_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ijrobp.2013.03.028","volume":"86","author":"M Shilkrut","year":"2013","unstructured":"Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(4):721\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"380_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"380_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3322\/caac.21333","volume":"66","author":"B Turkbey","year":"2016","unstructured":"Turkbey B, Brown AM, Sankineni S, Wood BJ, Pinto PA, Choyke PL. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate Cancer. CA Cancer J Clin. 2016;66(4):326\u201336.","journal-title":"CA Cancer J Clin"},{"key":"380_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3389\/fonc.2016.00225","volume":"6","author":"C Testa","year":"2016","unstructured":"Testa C, Pultrone C, Manners DN, Schiavina R, Lodi R. Metabolic imaging in prostate Cancer: where we are. Front Oncol. 2016;6:225.","journal-title":"Front Oncol"},{"key":"380_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cct.2015.07.004","volume":"44","author":"A Kanthabalan","year":"2015","unstructured":"Kanthabalan A, Shah T, Arya M, Punwani S, Bomanji J, Haroon A, Illing RO, Latifoltojar A, Freeman A, Jameson C, van der Meulen J, Charman S, Emberton M, Ahmed HU. The FORECAST study \u2014 focal recurrent assessment and salvage treatment for radiorecurrent prostate cancer. Contemp Clin Trials. 2015;44:175\u201386.","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"380_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S0090-4295(99)80455-5","volume":"47","author":"RA Edelstein","year":"1996","unstructured":"Edelstein RA, Zietman AL, De Las MA, Krane RJ, Babayan RK, Dallow KC, Moreland RB. Implications of prostate micro-metastases in pelvic lymph nodes: an archival tissue study. Urology. 1996;47(3):370\u20135.","journal-title":"Urology."},{"issue":"2","key":"380_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/1874471011306020005","volume":"6","author":"R Schiavina","year":"2013","unstructured":"Schiavina R, Ceci F, Borghesi M, Brunocilla E, Vagnoni V, Gacci M, Castellucci P, Nanni C, Martorana G, Fanti S. The dilemma of localizing disease relapse after radical treatment for prostate Cancer: which is the value of the actual imaging techniques? Curr Radiopharm. 2013;6(2):92\u20135.","journal-title":"Curr Radiopharm"},{"issue":"2","key":"380_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","volume":"73","author":"S Gillessen","year":"2018","unstructured":"Gillessen S, Atard G, Beer TM, Beltran H, Bossi A, Bristow R, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol. 2018;73(2):178\u2013211.","journal-title":"Eur Urol"},{"issue":"5","key":"380_CR11","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/jmri.22542","volume":"33","author":"M Eiber","year":"2011","unstructured":"Eiber M, Holzapfel K, Ganter C, Epple K, Metz S, Geinitz H, Kubler H, Gaa J, Rummeny EJ, Beer AJ. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J Magn Reson Imaging. 2011;33(5):1160\u201370.","journal-title":"J Magn Reson Imaging"},{"issue":"5","key":"380_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/pros.22764","volume":"74","author":"V Pasoglou","year":"2014","unstructured":"Pasoglou V, Larbi A, Collette L, Annet L, Jamar F, Machiels JP, Michoux N, Vande Berg BC, Tombal B, Lecouvet FE. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified \u201call-in-one\u201d imaging approach? Prostate. 2014;74(5):496\u201377.","journal-title":"Prostate."},{"issue":"1","key":"380_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","volume":"62","author":"FE Lecouvet","year":"2012","unstructured":"Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, Machiels JB, Vande Berg B, Omoumi P, Tombal B. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc-99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol. 2012;62(1):68\u201375.","journal-title":"Eur Urol"},{"issue":"1","key":"380_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.juro.2017.02.071","volume":"198","author":"NL Robertson","year":"2017","unstructured":"Robertson NL, Sala E, Benz M, Landa J, Scardino P, Scher HI, Hricak H, Vargas HA. Combined whole body and multiparametric prostate magnetic resonance imaging as a 1-step approach to the simultaneous assessment of local recurrence and metastatic disease after radical prostatectomy. J Urol. 2017;198(1):65\u201370.","journal-title":"J Urol"},{"issue":"6","key":"380_CR15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.eururo.2011.11.008","volume":"61","author":"A Briganti","year":"2012","unstructured":"Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A, Colombo R, Freschi M, Rigatti P, Montorsi F. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol. 2012;61(6):1132\u20138.","journal-title":"Eur Urol"},{"issue":"6","key":"380_CR16","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.rcl.2012.08.004","volume":"50","author":"SS Talab","year":"2012","unstructured":"Talab SS, Preston MA, Elmi A, Tabatabaei S. Prostate cancer imaging: what the urologist wants to know. Radiol Clin N Am. 2012;50(6):1015\u201341.","journal-title":"Radiol Clin N Am"},{"issue":"5","key":"380_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1634\/theoncologist.2013-0027","volume":"18","author":"O Sartor","year":"2013","unstructured":"Sartor O, Eisenberger M, Kattan MW, Tombal B, Lecouvet F. Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist. 2013;18(5):549\u201357.","journal-title":"Oncologist"},{"issue":"2","key":"380_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.crad.2017.08.004","volume":"73","author":"CH Suh","year":"2018","unstructured":"Suh CH, Shinagare AB, Westenfield AM, Ramaiya NH, Van den Abbeele AB, Kim KW. Yield of bone scintigraphy for the detection of metastatic disease in treatment-na\u00efve prostate cancer: a systemic review and meta-analysis. Clin Radiol. 2018;73(2):158\u201367.","journal-title":"Clin Radiol"},{"key":"380_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000144059","volume":"81","author":"L Rinnab","year":"2008","unstructured":"Rinnab L, Mottaghy FM, Simon J, Volkmer BG, De Petriconi R, Hautman RE, et al. 11C choline PET\/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer: preliminary results of a prospective study. Urol Int. 2008;81:191\u20137.","journal-title":"Urol Int"},{"key":"380_CR20","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1097\/01.ju.0000123981.03084.06","volume":"171","author":"S Abuzallouf","year":"2004","unstructured":"Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171:2122\u20137.","journal-title":"J Urol"},{"issue":"3","key":"380_CR21","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1148\/radiol.2015151516","volume":"277","author":"PM Bossuyt","year":"2015","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF. STARD group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology. 2015;277(3):826\u201332.","journal-title":"Radiology."},{"issue":"10","key":"380_CR22","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.crad.2013.03.030","volume":"68","author":"APS Kirkham","year":"2013","unstructured":"Kirkham APS, Haslam P, Keanie JY, McCafferty I, Padhani AR, Punwani S, Richenberg J, Rottenberg G, Sohaib A, Thompson P, Turnbull LW, Sahdev A, Clements R, Carey BM, Allen C. Prostate MRI: Who, when, and how? Report from a UK consensus meeting. Clin Radiol. 2013;68(10):1016\u201323.","journal-title":"Clin Radiol"},{"issue":"6","key":"380_CR23","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1007\/s00330-018-5813-4","volume":"29","author":"EW Johnston","year":"2019","unstructured":"Johnston EW, Latifoltojar A, Sidhu HS, Ramachandran N, Sokolska M, Bainbridge A, et al. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging. Eur Radiol. 2019;29(6):3159\u201369.","journal-title":"Eur Radiol"},{"issue":"S3","key":"380_CR24","doi-asserted-by":"publisher","first-page":"S485","DOI":"10.21037\/tcr.2016.09.08","volume":"5","author":"BC Carthon","year":"2016","unstructured":"Carthon BC, Antonarakis ES. The STAMPEDE trial: paradigm-changing data through innovative trial design. Transl Cancer Res. 2016;5(S3):S485\u201390.","journal-title":"Transl Cancer Res"},{"issue":"1","key":"380_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bju.13972","volume":"121","author":"T Shin","year":"2018","unstructured":"Shin T, Smyth TB, Ukimura O, Ahmadi N, de Castro Abreu AL, Ohe C, et al. Diagnostic accuracy of a five-point Likert scoring system for magnetic resonance imaging (MRI) evaluated according to results of MRI\/ultrasonography image-fusion targeted biopsy of the prostate. BJU Int. 2018;121(1):77\u201383.","journal-title":"BJU Int"},{"issue":"7","key":"380_CR26","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate Cancer clinical trials working group. J Clin Oncol. 2008;26(7):1148\u201359.","journal-title":"J Clin Oncol"},{"issue":"12","key":"380_CR27","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402\u201318.","journal-title":"J Clin Oncol"},{"issue":"21","key":"380_CR28","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"key":"380_CR29","unstructured":"Value of PSA as a Tumour Marker. Available from: https:\/\/oncologypro.esmo.org\/content\/download\/98717\/1732452\/file\/ESMO-Preceptroship-prostate-cancer-lugano-november-2016-CASTRO.pdf ."},{"key":"380_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.7150\/jca.1.80","volume":"1","author":"CM Costelloe","year":"2010","unstructured":"Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80\u201392.","journal-title":"J Cancer"},{"issue":"14","key":"380_CR31","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","volume":"22","author":"T Hamaoka","year":"2004","unstructured":"Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22(14):2942\u201353.","journal-title":"J Clin Oncol"},{"issue":"2","key":"380_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):288\u201347.","journal-title":"Eur J Cancer"},{"issue":"1","key":"380_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00330-018-5445-8","volume":"29","author":"A Latifoltojar","year":"2019","unstructured":"Latifoltojar A, Punwani S, Lopes A, Humphries PD, Klusmann M, Menezes LJ, Daw S, Shankar A, Neriman D, Fitzke H, Clifton-Hadley L, Smith P, Taylor SA. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including 18F-FDG-PET-CT. Eur Radiol. 2019;29(1):202\u201312.","journal-title":"Eur Radiol"},{"key":"380_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13058-015-0561-8","volume":"17","author":"P Nuciforo","year":"2015","unstructured":"Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family receptors in breast cancer. Breast Cancer Res. 2015;17:53.","journal-title":"Breast Cancer Res"},{"key":"380_CR35","doi-asserted-by":"crossref","unstructured":"Taylor SA, Mallett S, Miles A, Beare S, Bhatnagar G, Bridgewater J, Glynne-Jones R, Goh V, Groves AM, Janes SM, Koh DM, Morris S, Morton A, Navani N, Oliver A, Padhani AR, Punwani S, Rockall AG, Halligan S. Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L). BMC Cancer. 2017 May;2;17(1):299.","DOI":"10.1186\/s12885-017-3281-x"},{"key":"380_CR36","doi-asserted-by":"crossref","unstructured":"Taylor SA, Mallett S, Beare S, et al. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective streamline C trial. Lancet Gastroenterol Hepatol. 2019; Epub ahead of print.","DOI":"10.3310\/hta23660"},{"key":"380_CR37","unstructured":"Taylor SA, Mallett S, Ball S, et al. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective streamline L trial. Lancet Resp. 2019; Epub ahead of print."},{"issue":"1","key":"380_CR38","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12885-016-2856-2","volume":"16","author":"E Johnston","year":"2016","unstructured":"Johnston E, Pye H, Bonet-Carne E, Panagiotaki E, Patel D, Galazi M, Heavey S, Carmona L, Freeman A, Trevisan G, Allen C, Kirkham A, Burling K, Stevens N, Hawkes D, Emberton M, Moore C, Ahmed HU, Atkinson D, Rodriguez-Justo M, Ng T, Alexander D, Whitaker H, Punwani S. INNOVATE: a prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer. BMC Cancer. 2016;16(1):816.","journal-title":"BMC Cancer"},{"issue":"1081","key":"380_CR39","doi-asserted-by":"publisher","first-page":"20170577","DOI":"10.1259\/bjr.20170577","volume":"91","author":"A Barnes","year":"2018","unstructured":"Barnes A, Alonzi R, Blackledge M, Charles-Edwards G, Collins DJ, Cook G, Coutts G, Goh V, Graves M, Kelly C, Koh DM, McCallum H, Miquel ME, O'Connor J, Padhani A, Pearson R, Priest A, Rockall A, Stirling J, Taylor S, Tunariu N, van der Meulen J, Walls D, Winfield J, Punwani S. UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. Br J Radiol. 2018 Jan;91(1081):20170577.","journal-title":"Br J Radiol"},{"issue":"1","key":"380_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, Sala E, Schlemmer HP, Petralia G, Vargas HA, Fanti S, Tombal HB, de Bono J. METastasis reporting and data system for prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate Cancer. Eur Urol. 2017;71(1):81\u201392.","journal-title":"Eur Urol"},{"issue":"2","key":"380_CR41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4103\/0972-3919.202255","volume":"32","author":"K Kallur","year":"2017","unstructured":"Kallur K, Ramachandra P, Rajkumar K, Swamy S, Desai I, Rao R, et al. Clinical utility of gallium-68 PSMA PET\/CT scan for prostate cancer. Indian J Nucl Med. 2017;32(2):110.","journal-title":"Indian J Nucl Med"},{"issue":"6","key":"380_CR42","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate Cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(6):926\u201337.","journal-title":"Eur Urol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-019-0380-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12880-019-0380-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-019-0380-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:05:36Z","timestamp":1605312336000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-019-0380-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["380"],"URL":"https:\/\/doi.org\/10.1186\/s12880-019-0380-y","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"23 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study abides by the principles of the Declaration of Helsinki and the UK Research Governance Framework version 2.LOCATE trial received UK Research Ethic Committee approval on 19th of June 2015 by the NRES Committee London-Chelsea with REC reference \/LO\/0776 and is registered on  with reference number NCT02935816.Written informed consent were obtained from all study participants.Findings from this research will be disseminated at conferences and submitted for peer-reviewed publications.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study has not received any funding\/assistance from a commercial organisation. The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}